INTERACTION BETWEEN STRUCTURAL, STATISTICAL, AND COVARIATE MODELS IN POPULATION PHARMACOKINETIC ANALYSIS

被引:54
作者
WADE, JR
BEAL, SL
SAMBOL, NC
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143
[3] UNIV UPPSALA,DIV PHARMACOKINET,S-75123 UPPSALA,SWEDEN
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1994年 / 22卷 / 02期
关键词
POPULATION PHARMACOKINETICS; STRUCTURAL MODEL; COVARIATE MODEL; NONMEM; MODEL SELECTION;
D O I
10.1007/BF02353542
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of the choice of pharmacokinetic model on subsequent determination of covariate relationships in population pharmacokinetic analysis was studied using both simulated and real data sets. Simulations and data analysis were both performed with the program NONMEM. Data were simulated using a two-compartment model, but at late sample times, so that preferential selection of the two-compartment model should have been impossible. A simple categorical covariate acting on clearance was included. Initially, on the basis of a difference in the objective function values, the two-compartment model was selected over the one-compartment model. Only when the complexity of the one-compartment model was increased in terms of the covariate and statistical models was the difference in objective function values of the two structural models negligible. For two real data sets, with which the two-compartment model was not selected preferentially, more complex covariate relationships were supported with the one-compartment model than with the two-compartment model. Thus, the choice of structural model can be affected as much by the covariate model as can the choice of covariate model be affected by the structural model; the two choices me interestingly intertwined. A suggestion on how to proceed when building population pharmacokinetic models is given.
引用
收藏
页码:165 / 177
页数:13
相关论文
共 34 条
[1]   POPULATION PHARMACOKINETICS OF TOBRAMYCIN [J].
AARONS, L ;
VOZEH, S ;
WENK, M ;
WEISS, P ;
FOLLATH, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :305-314
[2]   AN EVALUATION OF POPULATION PHARMACOKINETICS IN THERAPEUTIC TRIALS .3. PROSPECTIVE DATA-COLLECTION VERSUS RETROSPECTIVE DATA ASSEMBLY [J].
ANTAL, EJ ;
GRASELA, TH ;
SMITH, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :552-559
[3]  
Beal SL., 2022, NONMEM 7 4 USERS GUI
[4]   POTENTIAL OF POPULATION PHARMACOKINETICS TO REDUCE THE FREQUENCY OF BLOOD-SAMPLING REQUIRED FOR ESTIMATING KINETIC-PARAMETERS IN NEONATES [J].
COLLART, L ;
BLASCHKE, TF ;
BOUCHER, F ;
PROBER, CG .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1992, 18 (1-2) :71-80
[5]   NETILMICIN IN THE NEONATE - POPULATION PHARMACOKINETIC ANALYSIS AND DOSING RECOMMENDATIONS [J].
FATTINGER, K ;
VOZEH, S ;
OLAFSSON, A ;
VLCEK, J ;
WENK, M ;
FOLLATH, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (01) :55-65
[6]   POPULATION PHARMACOKINETICS OF QUINIDINE [J].
FATTINGER, K ;
VOZEH, S ;
HA, HR ;
BORNER, M ;
FOLLATH, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) :279-286
[7]   EXPERIENCES IN THE APPLICATION OF NONMEM TO PHARMACOKINETIC DATA-ANALYSIS [J].
FLUHLER, H ;
HUBER, H ;
WIDMER, E ;
BRECHBUHLER, S .
DRUG METABOLISM REVIEWS, 1984, 15 (1-2) :317-339
[8]   POPULATION PHARMACOKINETICS OF ZIDOVUDINE [J].
GITTERMAN, SR ;
DRUSANO, GL ;
EGORIN, MJ ;
STANDIFORD, HC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :161-167
[9]   AN EVALUATION OF POPULATION PHARMACOKINETICS IN THERAPEUTIC TRIALS .2. DETECTION OF A DRUG-DRUG INTERACTION [J].
GRASELA, TH ;
ANTAL, EJ ;
ERESHEFSKY, L ;
WELLS, BG ;
EVANS, RL ;
SMITH, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) :433-441
[10]   AN EVALUATION OF POPULATION PHARMACOKINETICS IN THERAPEUTIC TRIALS .1. COMPARISON OF METHODOLOGIES [J].
GRASELA, TH ;
ANTAL, EJ ;
TOWNSEND, RJ ;
SMITH, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (06) :605-612